Intervention Review

You have free access to this content

Herbal medicines for fatty liver diseases

  1. Zhao Lan Liu1,
  2. Liang Zhen Xie2,
  3. Jiang Zhu3,
  4. George Q Li4,
  5. Suzanne J Grant5,
  6. Jian Ping Liu1,*

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 24 AUG 2013

Assessed as up-to-date: 31 MAY 2012

DOI: 10.1002/14651858.CD009059.pub2


How to Cite

Liu ZL, Xie LZ, Zhu J, Li GQ, Grant SJ, Liu JP. Herbal medicines for fatty liver diseases. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD009059. DOI: 10.1002/14651858.CD009059.pub2.

Author Information

  1. 1

    Beijing University of Chinese Medicine, Centre for Evidence-Based Chinese Medicine, Beijing, China

  2. 2

    First Hospital Affiliated to Heilongjiang University of Traditional Chinese Medicine, Haerbin, Heilongjiang Province, Heilongjiang Province, China

  3. 3

    Beijing University of Chinese Medicine, College of Humanities, Beijing, China

  4. 4

    University of Sydney, Faculty of Pharmacy, Sydney, NSW, Australia

  5. 5

    University of Western Sydney, Center for Complementary Medicine Research, Sydney, New South Wales, Australia

*Jian Ping Liu, Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, 11 Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China. jianping_l@hotmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 24 AUG 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Cao 2011 {published data only}
  • Cao WZ, Hou WL, Wang HB. Clinical observation on nonalcoholic fatty liver treated with Huazhuo Xiaozhi decoction combined with bicyclol, a report of 62 cases 2011. Hebei Journal Traditional Chinese Medicine 2011;33(7):998-9.
Chen 2007a {published data only}
  • Chen GL, Zhou YY, Luo LD, Xu SJ, Zhou FS. Effect of Zhigan prescription for the treatment of non-alcoholic fatty liver: an observation of 30 cases. Journal of New Chinese Medicine 2007;39(8):30-4.
Chen 2007b {published data only}
  • Chen HL, Ouyang Q. Clinical observation of NAFLD treating by Jiangzhi baogan decoction. Journal of Practical Traditional Chinese Medicine 2007;23(6):354.
Chen 2010 {published data only}
  • Chen YC. Clinical observation of Hua Tan Huo Xue decoction on treatment of 47 cases of nonalcoholic steatohepatitis. Guiding Journal of Traditional Chinese Medicine and Pharmacology 2010;16(10):32-3.
Cheng 2006 {published data only}
  • Cheng JJ, Peng R, Wu QK. Clinical study on treatment of fatty liver disease treated by Zhiyan xiao decoction. Hubei Journal of Traditional Chinese Medicine 2006;28(10):7-8.
Chou 2006 {published data only}
  • Chou SC, Chen KW, Hwang JS, Lu WT, Chu YY, Lin JD, et al. The add-on effects of Gynostemma pentaphyllum on nonalcoholic fatty liver disease. Alternative Therapies in Health and Medicine 2006;12(3):34-9. [PUBMED: 16708768]
Dai 2009 {published data only}
  • Dai DQ, Gao JL, Qin L, Yang SY, Chi J. Clinical observation of treatment of Shuli QIingzhi powder on 60 cases of fatty liver. Journal of Hebei North University (Medical Edition) 2009;26(5):53-5.
Dang 2007 {published data only}
  • Dang ZQ, Zhao CP, Dang ZF, Wang YL. Therapeutic observation on Shiwei Ganzhikang capsule in treating non alcoholic fatty liver (type of phlegm and blood stasis in the interior). Henan Traditional Chinese Medicine 2007;27(1):37-9.
Deng 2003a {published data only}
  • Deng JG, Qin HZ, Lin SN, Huang B. Clinical observation on Huanglongganzhixiao decoction treating 50 cases of hyperlipidemia fatty liver. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine 2003;13(9):537-8.
Deng 2010 {published data only}
  • Deng X. Treatment of Xiaoyao pills and legalon on 39 cases of nonalcoholic fatty liver disease. Hubei Journal of Traditional Chinese Medicine 2010;32(11):34.
Fei 2009 {published data only}
  • Fei ZY, Chen YM, Guan M. Effect of Yuqin capsule on cytokins in treating non-alcoholic fatty liver disease patients. Fudan University Journal of Medicine Science 2009;36(3):296-99.
Gu 2007a {published data only}
  • Gu CL, Zhang YK, Fu YX, Yang SF, Li XQ. Effect of Tiaozhi Yanggan decoction in treating patients with non-alcoholic fatty liver. Chinese Journal of Integrative Medicine 2007;13(4):275-9.
Gu 2007b {published data only}
  • Gu JX, Xiao MZ, Xu JL, Li XD. Clinical study of pattern identification of Chinese medicine combined with Silybininon capsule in the treatment of fatty liver disease. Hubei Journal of Traditional Chinese Medicine 2007;29(10):31-2.
Guan 2010 {published data only}
  • Guan XJ, Li GL, Zhang ZM, Zou YQ, Lan XQ. Clinical observation on fatty liver treated by wild apricot in Xinjiang Uighur nationality. Chinal Journal of Traditional Chinese Medicine and Pharmacy 2010;25(3):473-5.
Guo 2007 {published data only}
  • Guo XJ, Mao WW, Wu R, Hou BF. 36 case of NASH treated by Hegan decoction combined with tiopronin. Journal of Shaanxi College of Traditional Chinese Medicine 2007;30(6):23-4.
Guo 2010 {published data only}
  • Guo XZ, Wang B, Yi SH. Clinical observation of treatment of Xiaogan Jiangzhi formula on 32 cases of nonalcoholic fatty liver disease. Inner Mongol Journal of Traditional Chinese Medicine 2010;29(12):8-9.
Hu 2010 {published data only}
  • Hu AM, Yan L. Clinical observation of treatment of Tangganjian on diabetes 2 with fatty liver disease complication. Hubei Journal of Traditional Chinese Medicine 2010;32(10):16-8.
Huang 2005 {published data only}
  • Huang GY, Hu ZB. Preservation of Shugan Lipi Huoxue San combined with GSH on treating fatty liver diseases. Journal of Sichuan of Traditional Chinese Medicine 2005;23(1):42-3.
Huang 2011 {published data only}
  • Huang HN, Mao DW, Huang JJ. Clinical observation of Quyu Huazhuo decoction for nonalcoholic liver disease with abnormal liver function. Journal of New Chinese Medicine 2011;43(2):44-6.
Huo 2008 {published data only}
  • Huo LY, Wang S, Sheng J. Treatment of Kezhi capsules combining polyene phosphatidylcholine on 38 cases of nonalcoholic steatohepatitis. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 2008;18(3):171-2.
Ji 2005 {published data only}
  • Ji G, Fan JG, Chen JJ, Lu LG, Xin LJ, Zheng PY, et al. Clinical study on treatment of non-alcoholic fatty liver of damp-heat syndrome type by Danning tablet. Chinese Journal of Integrated Traditional and Western Medicine 2005;25(6):485-7.
Jia 2003 {published data only}
  • Jia JP, Lin S. Clinical observation on 102 cases of alcoholic fatty liver treated with Juge Yigan decoction. Journal of Traditional Chinese Medicine 2003;44(10):750-1.
Jia 2009 {published data only}
  • Jia JJ, Zhu ZY. Treatment of Shengqing Jiangzhuo therapy combined with changing lifestyle on 62 cases of nonalcoholic fatty liver. Shandong Journal of Traditional Chinese Medicine 2009;28(7):464-6.
Jiang 2009 {published data only}
  • Jiang JM. Effect of Zhishi Xiaopi Tang on nonalcoholic fatty liver of phlegm-dampness obstruction. World Chinese Medicine 2009;4(5):246-7.
Kong 2010 {published data only}
  • Kong M, Zho XJ, Xing CY, Shu XC. A randomized control trial about regulating liver to lowering lipid granules treating NAFLD. Journal of Liaoning University of TCM 2010;12(12):103-5.
Li 2005 {published data only}
  • Li SJ, Lin L, Wang L. 45 cases of Huoxue Qinggan Tang combined with polyene phosphatidylcholine capsules on treating alcoholic hepatitis. Shaanxi Journal of Traditional Chinese Medicine 2005;26(1):7-9.
Li 2006a {published data only}
  • Li YG, Zhang J, Yang TY, Guo ZC. Clinical observation on treatment of NAFLD and its risk factors by Xiaozhi powder. Fujian Journal of Traditional Chinese Medicine 2006;37(3):1-2.
Li 2006b {published data only}
  • Li YS, Yang H. 40 cases of fatty liver treated by Baogan Xiaozhi pellet. Journal of Practical Traditional Chinese Internal Medicine 2006;20(4):222-3.
Li 2007 {published data only}
  • Li YF, Ma LN. Clinical observation of 36 cases of steato-hepatitis treated by Shuanghu qinggan granule. Chinese Journal of Information on Traditional Chinese Medicine 2007;14(12):61.
Li 2008 {published data only}
  • Li BL, Luo R, Liu YZ, Li WJ. Effects of fortify the spleen and resolve phlegm on serum SOD and MDA in patients with non-alcoholic fatty liver disease. Liaoning Journal of Traditional Chinese Medicine 2008;35(7):992-4.
Li 2009 {published data only}
  • Li WB. Clinical observation on Qinggan decoction to treat non-alcoholic fatty liver. Journal of Sichuan of Traditional Chinese Medicine 2009;27(7):64-5.
Li 2010 {published data only}
  • Li DF, Bai XG, Wei AX, Lei HQ. Clinical observation of treatment of Xiaotan Jiangzhi formula combined with polyene phosphatidylcholine on nonalcoholic fatty liver disease. Guiding Journal of Traditional Chinese Medicine and Pharmacy 2010;16(9):48-9.
Liang 2008 {published data only}
  • Liang XL, Wang ZY, Li XL, Guo XZ, Su Y, Wang CL. Clinical effect of colon herbs dialysis therapy in treating non-alcoholic fatty liver disease. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine 2008;18(6):340-1.
Liang 2010 {published data only}
  • Liang DY, Ge Y, Shen CG. Clinical study of Jianpi Huazhuo decoction on treatment of nonalcoholic steatohepatitis. Contemporary Medicine 2010;16(21):19-21.
Liang 2011 {published data only}
  • Liang GY, Xie JR. Clinical study on treatment of fatty liver disease treated by Baogan Xiaozhi particle 2011. Information on Traditional Chinese Medicine 2011;28(2):46-8.
Lin 2010a {published data only}
  • Lin L, Zhang QQ. Clinical study of prevention and treatment of Xiaozhi Jianpi decoction on nonalcoholic steatohepatitis. Traditional Chinese Medicine Journal 2010;9(4):44-6.
Lin 2010b {published data only}
  • Lin ZR, Fan H, Deng X, Wu QK. Clinical observation of treatment of self-prescripted Jianpi Huatan formula on 57 cases of nonalcoholic steatohepatitis. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 2010;20(1):48-9.
Lin 2011 {published data only}
  • Lin YW, Zhang SJ, Chen ZX, Sun BG, Xiang T, Chen XL. The effects of Yunpi Tongluo prescription on nonalcoholic fatty liver disease 2011. Journal of Chinese Medicinal Materials 2011;34(7):1158-62.
Liu 2008 {published data only}
  • Liu YJ, Guo F, Zeng BF. Clinical study on Qiyin granules in treating non-alcoholic fatty liver disease of liver depression and spleen deficiency pattern. Xinjiang Journal of Traditional Chinese Medicine 2008;26(3):8-10.
Liu 2009 {published data only}
  • Liu XX, Zhang YX. Effect of Xiaoyu Huatan Yin on insulin resistance of non-alcoholic fatty liver disease. Hebei Journal of Traditional Chinese Medicine 2009;31(7):982-4.
Lou 2008 {published data only}
  • Lou SY, Liu Y, Ma YY, Chen HY, Chen WH, Ying J, et al. Effects of Yiqi Sanju formula on non-alcoholic fatty liver disease: a randomized controlled trial. Journal of Chinese Integrative Medicine 2008;6(8):793-8.
Ma 2009 {published data only}
  • Ma YP, Zhao L, Peng J, Luo GY, Huang XZ, Wang Y. Treatment of Zhiganqing granules on 30 cases of nonalcoholic chronic steatohepatitis. Shanxi Journal of Traditional Chinese Medicine 2009;30(6):684-5.
Ma 2010 {published data only}
  • Ma J, Sun Y, Huang RZ. Clinical observation of Qinggan Xiaozhi decoction on treatment of nonalcoholic steatohepatitis. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine 2010;10(2):5-6.
Mi 2010 {published data only}
  • Mi YQ, Cao WK, Xu L, Zhen SW, Pan ZH, Ping L, et al. Clinical study on effect of Jiangan Jiangzhi pill in treating nonalcoholic fatty liver diseases. Liaoning Journal of Traditional Chinese Medicine 2010;37(1):97-9.
Pu 2009 {published data only}
  • Pu ZP, Hua HB. Treatment of modified Wendan decoction on 53 cases of nonalcoholic fatty liver. Jiangsu Journal of Traditional Chinese Medicine 2009;41(7):42-3.
Song 2006 {published data only}
  • Song B, Wen WB, Liu J. Clinical observation of 42 cases of NASH treated by diammonium glycyrrhizinate capsule combined with Panax Notoginseng powder. Yunnan Journal of Traditional Chinese Medicine and Materia Medica 2006;27(2):6-7.
Wang 2006 {published data only}
  • Wang G, Yao Y, Wang HT. Clinical observation of 36 cases of AFL treated by tiopronin combined with Chuige Jiugan decoction. Journal of Sichuan of Traditional Chinese Medicine 2006;24(7):42-3.
Wang 2008a {published data only}
  • Wang JQ, Zhang J, Xue FM, Wang HF. Clinical observation of 64 cases on Sisheng Jiangzhi formula in treating non-alcoholic fatty liver disease. Beijing Journal of Traditional Chinese Medicine 2008;27(3):207-8.
Wang 2008b {published data only}
  • Wang YP, Yang YY, Chen LS, Zhang ZY, Yao QB, Zhuang MZ, et al. Clinical observation of "modified Jiangzhi Ligan decoction" in treating non-alcoholic fatty liver disease in phlegm-blood stasis constitution patients. Shanghai Journal of Traditional Chinese Medicine 2008;42(6):23-5.
Wang 2010 {published data only}
  • Wang XW, Wang D, Wang Z, Ha LF. Clinical investigation of Chaihu Shugan San on nonalcoholic fatty liver. Hebei Journal of Traditional Chinese Medicine 2010;32(8):1129-31.
Wang 2011a {published data only}
  • Wang H, Wang LY, Yang LD, Dong DC, Liu PX, Sun HR, et al. Clinical observation on nonalcoholic fatty liver treated with Tiaogan Lizhong decoction combined with Qingbai powder. Journal of Emergency in Traditional Chinese Medicine 2011;20(6):865, 868.
Wang 2011b {published data only}
  • Wang YX, Xu ZW, Fei M. Clinical study on treatment of fatty liver disease treated by Bushen Yipi prescription. Chinese Journal of Basic Medicine in Traditional Chinese Medicine 2011;17(3):296-7.
Wu 2006 {published data only}
  • Wu QK, Fan Q, Cheng QJ. 40 cases of fatty liver treated by Shanzha beimu decoction. Chinese Journal of Integrated Traditional and Western Medicine on Digestion 2006;14(1):54-5.
Wu 2008 {published data only}
  • Wu BL. Clinical studies on Chinese herbal formulas for non alcohol fatty liver diseases. Liaoning Journal of Traditional Chinese Medicine 2008;35(5):731-2.
Wu 2010 {published data only}
  • Wu SX, Wu SD, Yang KD, Long YZ. Treatment of self-precripted Chailing decoction on 33 cases of nonalcoholic fatty liver. Global Traditional Chinese Medicine 2010;3(3):200-2.
Xin 2005 {published data only}
  • Xin W, Li XF, Liao YF. The treatment of Qingre Huatan Huoxue Fa on treating non-alcoholic fatty liver disease, a report of 30 cases. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 2005;15(5):303-4.
Xu 2008 {published data only}
  • Xu M, Guo JZ, Xia M, Zhan Q. Clinical observation of non-alcoholic fatty liver disease treating by Huganning tablet combined with metformin. Chinese Journal of Integrated Traditional and Western Medicine on Digestion 2008;16(5):329-30.
Xu 2010 {published data only}
  • Xu CR, Zhen Y, Ma J. Clinical study of treating 60 cases of alcoholic fatty liver by Jiejiu Hugan Tang combining with western medicine. Chinese Journal of Ethnomedicine and Ethnopharmacy 2010;19(18):102-3.
Yang 2004 {published data only}
  • Yang GW, Ge Q, Jiang SY, Shen SY, Yu XY. The treatment of Xiaozhi Jiangan Tang on non-alcoholic fatty liver diseases. Clinical Journal of Traditional Chinese Medicine 2004;16(5):431-2.
Yang 2005 {published data only}
  • Yang LQ, Yi ZG, Su YQ, Hu YY, Ning FM. Clinical observation of Guben Xiaozhuo Tang on treating high blood-fat fatty liver diseases. Jiangxi Journal of Traditional Chinese Medicine 2005;36(1):23-4.
Yang 2006 {published data only}
  • Yang XJ, Li XL, Huang KW. Treatment of fatty liver diseases by Qingzhifugan decoction: a clinical observation of 32 cases. Zhejiang Journal of Traditional Chinese Medicine 2006;41(8):480.
Yang 2009 {published data only}
  • Yang ZH, Lei L, Huang XJ. Clinical analysis on nonalcoholic fatty liver treated by Shennong Ganzhining pill. Journal of Practical Traditional Chinese Medicine 2009;25(1):1-2.
Zeng 2007 {published data only}
  • Zeng YH, Lu DB. 30 cases of non-alcoholic fatty liver treating by Xiaozhi decoction. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 2007;17(3):174-5.
Zhang 2002 {published data only}
  • Zhang SJ, Chen ZX, Huang BJ, Lao SX. Observation on the method of clearing heat and removing dampness in treating alcoholic hepatitis. Chinese Journal of Integrated Traditional and Western Medicine on Gastro-Spleen 2002;10(3):145-7.
Zhang 2003 {published data only}
  • Zhang XW, Zhou M, Hu GQ. Clinical study on nonalcoholic steatohepatitis treated by ursodesoxycholic acid combined with Hugan tablet. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 2003;13(1):8-9.
Zhang 2005a {published data only}
  • Zhang P, Liu HM. The treatment of Quganzhi Tang Jiawei on fatty liver diseases, a report of 67 cases. Study Journal of Traditional Chinese Medicine 2005;23(5):944-5.
Zhang 2006a {published data only}
  • Zhang FM. Clinical analyses of 35 cases of NAFLD treated by Xuezhikang capsule. Chinese Journal of Primary Medicine and Pharmacy 2006;13(10):1682-3.
Zhang 2006b {published data only}
  • Zhang HH, Fan GY, Wu D. Clinical observation NAFLD treated by Ganzhikang capsule. Proceeding of Clinical Medicine 2006;15(9):657-8.
Zhang 2007 {published data only}
  • Zhang JJ, Zhang GY. The clinical study of therapy patients with nonalcoholic liver of fat with Sanyuhuzhuo decoction. Chinese Archives of Traditional Chinese Medicine 2007;25(1):176-8.
Zhang 2008 {published data only}
  • Zhang SJ, Chen ZX, Jiang KP, Cheng YH, Gu YL. The effect of Qu Yu Hua Tan Tong Luo decoction on the non-alcoholic steatohepatitis. Complementary Therapies in Medicine 2008;16(4):192-8.
Zhang 2011 {published data only}
  • Zhang SJ, Qi YY, Qian H, Li C, Lu QY, Ming LP, et al. Clinical study on treatment of nonalcoholic fatty liver of spleen-deficiency and damp-heatness syndrome type by Kangzhi prescription. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 2011;21(2):71-3.
Zhao 2009 {published data only}
  • Zhao HL, He HB. Treatment of Chinese medicine on 51 cases of nonalcoholic fatty liver. The Journal of Medical Theory and Practice 2009;22(7):810-1.
Zhao 2010 {published data only}
  • Zhao ZH, Wang ZG, Chen JL, Zeng BF. Clinical observation on the treatment of 112 non-alcoholic fatty liver patients (liver stagnation and spleen deficiency type) with of Qiyin tea. Yunnan Journal of Traditional Chinese Medicine and Materia Medica 2010;31(5):21-2.
Zhou 2008 {published data only}
  • Zhou YA, Liu JM, Shi YX. Observation on effects of treating fatty liver by Kezhi capsule. Chinese Medicine Modern Distance Education of China 2008;6(8):850-2.
Zhou 2009 {published data only}
  • Zhou B, Cai GX, Bai ZP, Zeng SL, Fu SH. Clinical observation of 60 cases on Lishi Huoxue Tongluo decoction in treating non-alcoholic steatohepatitis. Guiding Journal of Traditional Chinese Medicine and Pharmacy 2009;15(7):13-5.
Zhu 2006 {published data only}
  • Zhu PS, Wang YL, Peng C. Treatment of non-alcoholic fatty liver by Zhixiao capsule: a clinical observation of 50 cases. New Journal of Traditional Chinese Medicine 2006;38(4):31-2.
Zhu 2010 {published data only}
  • Zhu YQ. Clinical study of Xiaotan Hugan decoction on treatment of 30 cases with fatty liver disease. Shanxi Journal of Traditional Chinese Medicine 2010;31(5):527-8.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Deng 2003 {published data only}
  • Deng DQ, Jin HY. The treatment of Shugan Jianpi Huashi Tang on fatty liver diseases, a report of 35 cases. Jiangsu Journal of Traditional Chinese Medicine 2003;24(10):30-1.
Deng 2005 {published data only}
  • Deng YQ, Fan XF, Li YD. Clinical observation on treatment of non-alcoholic fatty liver diseases by Silyben. China Journal of Chinese Materia Medica 2005;30(13):1044-5.
Gao 2002 {published data only}
  • Gao ZL, Hu XH, Wu X, Cheng FT. Clinical research on Shaji Keli treating liver fibrosis. China Journal of Chinese Medicine 2002;10(3):39-40.
Gao 2004 {published data only}
  • Gao J, Feng B. The treatment of alcoholic hepatitis with jaundice by the combination of Chinese traditional and Western medicine. Chinese Medical Record 2004;5(7):45-7.
Han 2011 {published data only}
  • Han HX, Jiang YD, Wang ZB, Li QW. Danggui Baizhu decoction treatment of alcoholic fatty liver in Singapore and Malaysia. Chinese Archives of Traditional Chinese Medicine 2011;29(2):435-7.
Huang 2000 {published data only}
  • Huang YQ, Wu XZ. Clinical research on Pingzhi Ji treating fatty liver diseases. Fujian Journal of Traditional Chinese Medicine 2000;31(4):3-5.
Ji 2004 {published data only}
  • Ji HP, Peng GB. Clinical observation on fatty liver treated with Jiangzhi Yigan pill, a report of 62 cases. Shanxi Journal of Traditional Chinese Medicine 2004;20(3):13-4.
Kang 2006 {published data only}
  • Kang Y, Chen R. 12 cases of fatty liver treated by Fugan Lipi Fang. Chinese Journal of Integrated Traditional and Western Medicine on Digestion 2006;14(5):342-3.
Li 2004 {published data only}
  • LI XH. Clinical observation of "liver discharging and blood-acting decoction" in treating fatty liver. Shanghai Journal of Traditional Chinese Medicine 2004;38(2):24-5.
Liu 2009a {published data only}
  • Liu YH. Theory and clinical study on treatment of non-alcoholic fatty liver diseases by Qingretongxia and Shuganlidan method. Wan Fang Thesis Database 2009.
Mohammadi 2010 {published data only}
  • Mohammadi HA, Shokri Shirvani J, Jabbari M. The efficacy of licorice root extract in decreasing transaminase activities in non-alcoholic fatty liver disease. Journal of Hepatology 2010;52 Suppl 1:S143.
Tao 2008 {published data only}
  • Tao L, Zhang SS. Clinical observation of 30 cases on Shugan Huazhuo Huoxue method in treating non-alcoholic fatty liver disease. China Journal of Traditional Chinese Medicine and Pharmacy 2008;23(6):552-3.
Wu 2008a {published data only}
  • Wu QQ. Treatment of Shuyuhuohua decoction on 80 cases of nonalcoholic fatty liver. Modern Journal of Integrated Traditional Chinese and Western Medicine 2008;17(24):3749-50.
Zhang 2005b {published data only}
  • Zhang CZ, Zhang AZ, Yan HM, Wang HM. Research on Jiangzhi Yigan Tang treating non-alcoholic fatty hepatitis. Sponsored By Hubei College of Traditional Chinese Medicine 2005;27(5):5-7.
Zhao 2003 {published data only}
  • Zhao H, Xu HM, Wei HG. Preservation of Qianggan Jiangzhi Tang on fatty liver diseases. Liaoning Journal of Traditional Chinese Medicine 2003;30(5):379.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Abdelmalek 2009
Adachi 2005
Adams 2005
Adams 2006
AGA 2002
  • American Gastroenterological Association. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 2002;123(5):1702-4.
Ahmed 2009
Assy 2010
  • Assy N, Djibre A, Farah R, Grosovski M, Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology 2010;254(2):393-400. [PUBMED: 20093511]
Bayard 2006
Beltowski 2009
  • Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins - mechanisms and consequences. Current Drug Safety 2009;4(3):209-28.
Brok 2008
  • Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61(8):763-9.
Brok 2009
  • Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98.
Browning 2004a
Browning 2004b
Caldwell 2010
Chen 1997
  • Haozhu Chen. Practice of Internal Medicine. People's Medical Publishing House, 1997.
Chen 2005
  • Haozhu Chen. Practice of Internal Medicine. People's Medical Publishing House, 2005.
China 2005
  • Ministry of Health of the People's Republic of China. Guidelines for Clinical Research of Traditional Chinese Drug Research. China Press of Traditional Chinese Medicine, 2005.
CMA 2000
  • Group of Epidemic disease and Verminosis, Society of Hepatology, Chinese Medical Association. National program for prevention and treatment of viral hepatitis. Chinese Journal of Hepatology 2000;8:324-9.
CMA 2001a
  • Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association. Diagnostic standard of non-alcoholic fatty liver (draft). Chinese Journal of Hepatology 2001;9(6):325.
CMA 2001b
  • Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association. Diagnostic standard of non-alcoholic fatty liver (draft). Chinese Hepatology 2001;6(3 Suppl 2):2.
CMA 2001c
  • Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association. Diagnostic standard of non-alcoholic fatty liver (draft). Chinese Journal of Hepatology 2001;9(5):264.
CMA 2002
  • Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association. Diagnostic standard of non-alcoholic fatty liver diseases. Modern Practical Medicine 2002;14(1):100.
CMA 2003a
  • Fatty Liver and Alcoholic Liver Diseases Study Group of Chinese Liver Disease Association, Chinese Medical Association. Diagnostic criteria of non-alcoholic fatty liver disease. Zhonghua Ganzangbing Zazhi 2003;11(2):71.
CMA 2003b
  • Fatty Liver and Alcoholic Liver Diseases Study Group of Chinese Liver Disease Association, Chinese Medical Association. Diagnostic criteria of alcoholic liver diseases. Zhonghua Ganzangbing Zazhi 2003;11(2):72.
CMA 2003c
  • Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association. Diagnostic standard of non-alcoholic fatty liver. Chinese Journal of Hepatology 2003;10(2):72.
CMA 2003d
  • Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association. Diagnostic standard of nonalcoholic fatty liver diseases. Chinese Journal of Hepatology 2003;11(1):73.
CMA 2006a
  • Group of Fatty Liver and Alcoholic Liver Diseases, Society of Heoatology, Chinese Medical Association. Guidelines for diagnosis and treatment of non-alcoholic fatty liver diseases. Chinese Hepatology 2006;11(1):68-70.
CMA 2006b
  • Group of Fatty Liver and Alcoholic Liver Diseases, Society of Heoatology, Chinese Medical Association. Guidelines for diagnosis and treatment of non-alcoholic fatty liver. Chinese Journal of Hepatology 2006;14(3):161-3.
CMA 2006c
  • Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association. Diagnostic standard of non-alcoholic fatty liver and alcoholic liver diseases. Chinese Journal of Hepatology 2006;3:1-4.
CMA 2006d
  • Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association. Diagnostic standard of nonalcoholic fatty liver diseases. Chinese Journal of Hepatology 2006;3:6.
CMA 2007
  • Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association. Guidelines for management of nonalcoholic fatty liver disease. Journal of Clinical Hepatology 2007;10(1):53.
Crabb 2004
CSHCMA 2007
  • Fatty Liver and Alcoholic Liver Disease Study Group of Chinese Society of Hepatology, Chinese Medical Association. The clinic guide of nonalcoholic fatty liver disease. Modern Digestion & Intervention 2007;12(4):266-8.
CTU 2011
  • Copenhagen Trial Unit. TSA - trial sequential analysis, 2011. ctu.dk/tsa/ (accessed 3 July 2013).
Denzer 2009
  • Denzer C, Thiere D, Muche R, Koenig W, Mayer H, Kratzer W, et al. Gender-specific prevalences of fatty liver in obese children and adolescents: roles of body fat distribution, sex steroids, and insulin resistance. Journal of Clinical Endocrinology and Metabolism 2009;94(10):3872-81. [PUBMED: 19773396]
Dienstag 2002
Dixon 2004
Dowman 2011
Egger 2003
  • Egger M, Jüni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technology Assessment 2003;7(1):1-76.
Eisenberg 1998
  • Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998;280(18):1569-75.
Fan 2007
  • Fan JG, Cai XB. The clinical guide of nonalcoholic fatty liver diseases for Asia-Pacific. Chinese Journal of Hepatology 2007;12(1):51-2.
Gagnier 2006
  • Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Annals of Internal Medicine 2006;144(5):364-7.
Gao 2008
  • Gao Y, Song LX, Jiang MN, Ge GY, Jia YJ. Effects of traditional Chinese medicine on endotoxin and its receptors in rats with non-alcoholic steatohepatitis. Inflammation 2008;31(2):121-32. [PUBMED: 18302012]
Gluud 2007
Gluud 2013
  • Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 6. Art. No.: LIVER.
Guajardo-Salinas 2010
  • Guajardo-Salinas GE, Hilmy A. Prevalence of nonalcoholic fatty liver disease (NAFLD) and utility of FIBROspect II to detect liver fibrosis in morbidly obese Hispano-American patients undergoing gastric bypass. Obesity Surgery 2010;20(12):1647-53. [PUBMED: 19957049]
Guallar 2005
  • Guallar E, Hanley DF, Miller ER 3rd. An editorial update: annus horribilis for vitamin E. Annals of internal medicine 2005; Vol. 143, issue 2:143-5. [PUBMED: 16027457]
Haentjens 2009
  • Haentjens P, Massaad D, Reynaert H, Peeters E, Van Meerhaeghe A, Vinken S, et al. Identifying non-alcoholic fatty liver disease among asymptomatic overweight and obese individuals by clinical and biochemical characteristics. Acta Clinica Belgica 2009;64(6):483-93. [PUBMED: 20101871]
Hamaguchi 2005
  • Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Annals of Internal Medicine 2005;143(10):722-8. [PUBMED: 16287793]
Harrison 2003
  • Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. American Journal of Gastroenterology 2003;98(11):2485-90. [PUBMED: 14638353]
    Direct Link:
He 2010
  • He M, Jiang J. Meta-analysis of effect of TCM on main biochemical indexes of non-alcoholic fatty liver disease. China Journal of Traditional Chinese Medicine and Pharmacy 2010;25(8):1214-20.
Higgins 2002
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hong 2007
Horie 2009
  • Horie Y, Kikuchi M, Yamagishi Y, Umeda R, Ebinuma H, Saito H, et al. Effect of a herbal medicine on fatty liver in rats fed ethanol chronically. Japanese Journal of Alcohol Studies & Drug Dependence 2009;44(6):636-48. [PUBMED: 20077758]
ICH-GCP 1997
  • International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice 1997 CFR & ICH Guidelines. Vol. 1, PA 19063-2043, USA: Barnett International/PAREXEL, 1997.
Jacobson 2009
  • Jacobson TA. Myopathy with statin-fibrate combination therapy: clinical considerations. Nature Reviews Endocrinology 2009; Vol. 5, issue 9:507-18.
Kjaergard 2001
  • Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
Lau 2006
Lazo 2008
Li 2002
  • Li YH, Zhang BL, Xu ZP, Shang HC. Systematical review on treating fatty liver with TCM by differentiation of symptom. Liaoning Journal of Traditional Chinese Medicine 2002;29(11):657-9.
Liang 1995
  • Kuohuang Liang. Hepatology. People's Medical Publishing House, 1995.
Liberati 2009
  • Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration. PLoS Medicine 2009;6(7):1-28.
Liu 2005
  • Liu YX, Wang JZH, Pang CHK, Jia HY. Chinese herbal medicines for fatty liver: a systematic review on randomized trials. Journal of Evidence-Based Medicine 2005;5(1):29-32.
Lundh 2012
Mayne 2006
  • Mayne TJ, Whalen E, Vu A. Annualized was found better than absolute risk reduction in the calculation of number needed to treat in chronic conditions. Journal of Clinical Epidemiology 2006;59:217-23.
Menon 2001
  • Menon KVN, Angulo P, Lindor KD. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. American Journal of Gastroenterology 2001;96(5):1631-4. [PUBMED: 11374713]
    Direct Link:
Moher 1998
  • Moher D, Pham B, Jones A, Cook D J, Jadad A R, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
Newton 2010
Preiss 2008
Promrat 2004
Rallidis 2004
  • Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004; Vol. 174, issue 1:193-6. [PUBMED: 15135271]
Rao 2004
  • Rao MS, Reddy JK. PPARalpha in the pathogenesis of fatty liver disease. Hepatology 2004; Vol. 40, issue 4:783-6. [PUBMED: 15382158]
Reddy 2006
  • Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. American Journal of Physiology. Gastrointestinal and Liver Physiology 2006;290(5):G852-8. [PUBMED: 16603729]
Review 1981
  • An international group. Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet 1981;1(8222):707-11. [PUBMED: 6110925]
RevMan 2011
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Royle 2003
  • Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
Sanyal 2002
  • Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123(5):1705-25. [PUBMED: 12404245]
Sanyal 2004
  • Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clinical Gastroenterology and Hepatology 2004;2(12):1107-15. [PUBMED: 15625656]
Savović 2012a
  • Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
Savović 2012b
  • Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
Schulz 1995
  • Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
Schulz 2010
  • Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ (Clinical Research Ed.) 2010;340:c332.
Schwimmer 2006
Sha 2009
  • Sha L. Clinical therapy of traditional Chinese medicine on fatty liver diseases. Chinese Community Doctors 2009;11(7):73-4.
Shi 2012
  • Shi KQ, Fan YC, Liu WY, Li LF, Chen YP, Zheng MH. Traditional Chinese medicines benefit to nonalcoholic fatty liver disease: a systematic review and meta-analysis. Molecular biology reports 2012;39(10):9715-22. [PUBMED: 22718512]
Stedman 2002
Sterne 2001
  • Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other biases. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care; Meta-analysis in Context. London: BMJ Publishing Group, 2001:189-208.
Stickel 2005
Thorlund 2009
  • Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses. International Journal of Epidemiology 2009;38(1):276-86.
Thorlund 2010
  • Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology 2010;2:57-66.
Thorlund 2011
  • Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for trial sequential analysis (TSA), 2011. ctu.dk/tsa/files/tsa_manual.pdf (accessed 18 July 2013).
Tsuruta 2010
  • Tsuruta G, Tanaka N, Hongo M, Komatsu M, Horiuchi A, Hamamoto K, et al. Nonalcoholic fatty liver disease in Japanese junior high school students: its prevalence and relationship to lifestyle habits. Journal of Gastroenterology 2010;45(6):666-72. [PUBMED: 20084525]
Ueno 1997
  • Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. Journal of Hepatology 1997;27(1):103-7. [PUBMED: 9252081]
Wang Y 2010
  • Wang Y, Dong J, Liu HY, Wang DQ, Tian YP. Biochemical characteristics and risk factors in non-alcoholic fatty liver. Frontiers in Bioscience (Elite Edition) 2010;2:105-10. [PUBMED: 20036859]
Wetterslev 2008
  • Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
Wetterslev 2009
  • Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology 2009;9:86.
Wood 2008
  • Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5.
Xie 2009
  • Xie RJ. Current status of the study of traditional Chinese medicine on fatty liver diseases. Modern Digestion & Intervention 2009;14(4):242-6.
Xu 2003
  • Xu LM, Hu YY. Studies on treatment of fatty liver with traditional Chinese medicine. Zhong Xi Yi Jie He Xue Bao 2003;1(2):138-41.
Yao 2004
  • Yao GB. Clinical Hepatology. 1st Edition. Shanghai: Science & Technology Press of Shanghai, 2004.
Zafrani 2004
Zakim 2003
  • Zakim D, Boyer TD, Montgomery C. Hepatology: a Textbook of Liver Disease. 4th Edition. Philadelphia: Saunders, 2003.
Zhang 2009
  • Zhang ZY, Wang F. Progress in the study of traditional Chinese prescription (mainly Danshen) on the treatment of fatty liver diseases. Chinese Journal of Integrated Traditional and Western Medicine 2009;19(2):126-8.